Cathepsin B abundance, activity and microglial localisation in Alzheimer's disease-Down syndrome and early onset Alzheimer's disease; the role of elevated cystatin B

被引:2
作者
Wu, Yixing [1 ]
Mumford, Paige [1 ]
Noy, Suzanna [2 ]
Cleverley, Karen [2 ]
Mrzyglod, Alicja [1 ]
Luo, Dinghao [1 ]
van Dalen, Floris [3 ,4 ]
Verdoes, Martijn [3 ,4 ]
Fisher, Elizabeth M. C. [2 ]
Wiseman, Frances K. [1 ]
机构
[1] UCL, UK Dementia Res Inst, Queen Sq, London WC1N 3BG, England
[2] UCL, Queen Sq Inst Neurol, Dept Neuromuscular Dis, Queen Sq, London WC1N 3BG, England
[3] Radboudumc, Dept Med Biosci, Geert Grooteplein Zuid 28, NL-6525 GA Nijmegen, Netherlands
[4] Inst Chem Immunol, Geert Grooteplein Zuid 28, NL-6525 GA Nijmegen, Netherlands
基金
英国医学研究理事会; 英国惠康基金;
关键词
Down syndrome; Alzheimer's disease; Cathepsin B; Cystatin B; MOUSE MODEL; UP-REGULATION; BRAIN; INDIVIDUALS; DYSFUNCTION; MEMORY;
D O I
10.1186/s40478-023-01632-8
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cathepsin B is a cysteine protease that is implicated in multiple aspects of Alzheimer's disease pathogenesis. The endogenous inhibitor of this enzyme, cystatin B (CSTB) is encoded on chromosome 21. Thus, individuals who have Down syndrome, a genetic condition caused by having an additional copy of chromosome 21, have an extra copy of an endogenous inhibitor of the enzyme. Individuals who have Down syndrome are also at significantly increased risk of developing early-onset Alzheimer's disease (EOAD). The impact of the additional copy of CSTB on Alzheimer's disease development in people who have Down syndrome is not well understood. Here we compared the biology of cathepsin B and CSTB in individuals who had Down syndrome and Alzheimer's disease, with disomic individuals who had Alzheimer's disease or were ageing healthily. We find that the activity of cathepsin B enzyme is decreased in the brain of people who had Down syndrome and Alzheimer's disease compared with disomic individuals who had Alzheimer's disease. This change occurs independently of an alteration in the abundance of the mature enzyme or the number of cathepsin B+ cells. We find that the abundance of CSTB is significantly increased in the brains of individuals who have Down syndrome and Alzheimer's disease compared to disomic individuals both with and without Alzheimer's disease. In mouse and human cellular preclinical models of Down syndrome, three-copies of CSTB increases CSTB protein abundance but this is not sufficient to modulate cathepsin B activity. EOAD and Alzheimer's disease-Down syndrome share many overlapping mechanisms but differences in disease occur in individuals who have trisomy 21. Understanding this biology will ensure that people who have Down syndrome access the most appropriate Alzheimer's disease therapeutics and moreover will provide unique insight into disease pathogenesis more broadly.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] The Search for Biomarkers of Alzheimer's Disease in Down Syndrome
    Handen, Benjamin L.
    AJIDD-AMERICAN JOURNAL ON INTELLECTUAL AND DEVELOPMENTAL DISABILITIES, 2020, 125 (02): : 97 - 99
  • [32] Bioavailable estradiol and age at onset of Alzheimer's disease in postmenopausal women with Down syndrome
    Schupf, Nicole
    Winsten, Susan
    Patel, Bindu
    Pang, Deborah
    Ferin, Michel
    Zigman, Warren B.
    Silverman, Wayne
    Mayeux, Richard
    NEUROSCIENCE LETTERS, 2006, 406 (03) : 298 - 302
  • [33] Association between Inflammatory Conditions and Alzheimer's Disease Age of Onset in Down Syndrome
    Lai, Florence
    Mercaldo, Nathaniel
    Wang, Cassandra M.
    Hersch, Giovi G.
    Rosas, Herminia Diana
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (14)
  • [34] Cathepsin B-A Neuronal Death Mediator in Alzheimer's Disease Leading to Neurodegeneration
    Sharma, Anjali
    Swetha, Rayala
    Bajad, Nilesh Gajanan
    Ganeshpurkar, Ankit
    Singh, Ravi
    Kumar, Ashok
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2022, 22 (15) : 2012 - 2023
  • [35] What can we learn from study of Alzheimer's disease in patients with Down syndrome for early-onset Alzheimer's disease in the general population?
    Robyn A Wallace
    Arthur J Dalton
    Alzheimer's Research & Therapy, 3
  • [36] Higher Cathepsin B Levels in Plasma in Alzheimer's Disease Compared to Healthy Controls
    Sundelof, Johan
    Sundstrom, Johan
    Hansson, Oskar
    Eriksdotter-Jonhagen, Maria
    Giedraitis, Vilmantas
    Larsson, Anders
    Degerman-Gunnarsson, Malin
    Ingelsson, Martin
    Minthon, Lennart
    Blennow, Kaj
    Kilander, Lena
    Basun, Hans
    Lannfelt, Lars
    JOURNAL OF ALZHEIMERS DISEASE, 2010, 22 (04) : 1223 - 1230
  • [37] Deteriorative factor and microglial role in Alzheimer's disease
    Takata, Kazuyuki
    Kitamura, Yoshihisa
    Shimohama, Shun
    Taniguchi, Takashi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2005, 125 : 114 - 117
  • [38] Alzheimer's Disease in the Down Syndrome: An Overview of Genetics and Molecular Aspects
    Gomes, Fabiana de C.
    Mattos, Marlon F.
    Goloni-Bertollo, Eny M.
    Pavarino, Erika C.
    NEUROLOGY INDIA, 2021, 69 (01) : 32 - 41
  • [39] Noradrenergic System in Down Syndrome and Alzheimer's Disease A Target for Therapy
    Phillips, Cristy
    Fahimi, Atoossa
    Das, Devsmita
    Mojabi, Fatemeh S.
    Ponnusamy, Ravikumar
    Salehi, Ahmad
    CURRENT ALZHEIMER RESEARCH, 2016, 13 (01) : 68 - 83
  • [40] Timing of Alzheimer's Disease by Intellectual Disability Level in Down Syndrome
    Hartley, Sigan L.
    Fleming, Victoria
    Schworer, Emily K.
    Peven, Jamie
    Handen, Benjamin L.
    Krinsky-McHale, Sharon
    Hom, Christy
    Lee, Laisze
    Tudorascu, Dana L.
    Laymon, Charles
    Minhas, Davneet
    Luo, Weiquan
    Cohen, Annie
    Zaman, Shahid
    Ances, Beau M.
    Mapstone, Mark
    Head, Elizabeth
    Lai, Florence
    Rosas, H. Diana
    Klunk, William
    Christian, Bradley
    JOURNAL OF ALZHEIMERS DISEASE, 2023, 95 (01) : 213 - 225